Tuesday, August 20, 2019 Daily Archives

Commercial N-1 perfusion carried out by Samsung BioLogics

by

CDMO Samsung BioLogics has used an Alternating Tangential Flow (ATF) system to perform N-1 perfusion at its 180,000 L facility in South Korea. Contract development and manufacturing organization (CDMO) Samsung BioLogics opened its number 3 facility at its site in Songdo, Incheon last year, boasting 180,000 L of commercial stainless steel bioreactor capacity. This month, the firm has announced it has successfully carried out N-1 perfusion with an Alternating Tangential Flow (ATF) system at the 3,000 L scale to supply…

August 20, 2019

Evotec eyes US commercial biomanufacturing pod

by

Months after buying platform firm Just.Bio, Evotec says it is evaluating the construction of the first modular J.POD for commercial manufacturing later this year. In May, German R&D services firm Evotec launched itself into the large molecule space through the $90 million (€81 million) acquisition of Just.Bio. The deal added several platform technologies aimed at reducing the cost of goods for proteins, including a large molecule manufacturing design platform, known as J.DESIGN and JP3, a lab and computational tool for…

August 20, 2019

New Zealand? Firm eyes US ops to prep for commercial peptides

by

Zealand Pharma has taken its first steps to build US commercial operations with an aim to launch four peptides over the next five years. According to Zealand Pharma CEO Emmanuel Dulac, the Danish biotech has “one of the most predictive and promising platforms†in the therapeutic peptide space, and 20 years of discovery and R&D are rapidly approaching fruition. “We have proven that we can take multiple programs through the clinics and execute on them according to industry benchmarks. To…

August 20, 2019